| P2093 | author name string | Quan Jiang | |
| | Guangdi Wang | |
| | Shilong Zheng | |
| P2860 | cites work | Novel Aromatase Inhibitors by Structure-Guided Design | Q27672328 |
| | Rhodacyanine derivative selectively targets cancer cells and overcomes tamoxifen resistance | Q28482597 |
| | Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer | Q29620676 |
| | Long-term treatment with tamoxifen facilitates translocation of estrogen receptor alpha out of the nucleus and enhances its interaction with EGFR in MCF-7 breast cancer cells | Q30442854 |
| | Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group | Q32020808 |
| | Steroid hormone receptors in breast cancer management | Q33539154 |
| | Antitumor agents. 272. Structure-activity relationships and in vivo selective anti-breast cancer activity of novel neo-tanshinlactone analogues. | Q33770219 |
| | Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer | Q33845160 |
| | Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a phase II trial | Q33928271 |
| | Characterization of the pharmacophore properties of novel selective estrogen receptor downregulators (SERDs). | Q34047079 |
| | Experimental treatment of oestrogen receptor (ER) positive breast cancer with tamoxifen and brivanib alaninate, a VEGFR-2/FGFR-1 kinase inhibitor: a potential clinical application of angiogenesis inhibitors | Q34082909 |
| | Endoxifen, a new cornerstone of breast cancer therapy: demonstration of safety, tolerability, and systemic bioavailability in healthy human subjects | Q34146176 |
| | The estrogen receptor: a model for molecular medicine. | Q34204428 |
| | Both N- and C-terminal transactivation functions of DNA-bound ERalpha are blocked by a novel synthetic estrogen ligand | Q34284430 |
| | 3-[4-(1,2-Diphenylbut-1-enyl)phenyl]acrylic acid: a non-steroidal estrogen with functional selectivity for bone over uterus in rats | Q34342405 |
| | TAS-108: a novel steroidal antiestrogen. | Q34392579 |
| | Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate | Q34516345 |
| | A phase II trial of Afimoxifene (4-hydroxytamoxifen gel) for cyclical mastalgia in premenopausal women | Q34577402 |
| | Selective estrogen-receptor modulators and antihormonal resistance in breast cancer | Q34692670 |
| | CYP2D6 and tamoxifen: DNA matters in breast cancer | Q34993830 |
| | A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer | Q35034708 |
| | Antiestrogens and selective estrogen receptor modulators as multifunctional medicines. 1. Receptor interactions | Q35079156 |
| | Aromatase inhibitors in breast cancer | Q35152297 |
| | Randomized, double-blind, multicenter trial comparing two doses of arzoxifene (LY353381) in hormone-sensitive advanced or metastatic breast cancer patients. | Q35211301 |
| | Cross-talk between notch and the estrogen receptor in breast cancer suggests novel therapeutic approaches | Q35652417 |
| | Endocrine treatment options for advanced breast cancer--the role of fulvestrant | Q36030081 |
| | Sequencing of aromatase inhibitors | Q36229445 |
| | Treatment of Postmenopausal Breast Cancer with Selective Estrogen Receptor Modulators (SERMs). | Q36569158 |
| | The fight against tamoxifen resistance in breast cancer therapy: a new target in the battle? | Q36752587 |
| | Fulvestrant (Faslodex) -- how to make a good drug better | Q36900695 |
| | Boron-Based 4-Hydroxytamoxifen Bioisosteres for Treatment of de Novo Tamoxifen Resistant Breast Cancer | Q37014147 |
| | Targeting Src in breast cancer | Q37167029 |
| | The Effect of Selective Estrogen Receptor Modulators (SERMs) on the Tamoxifen Resistant Breast Cancer Cells | Q37326230 |
| | Advances in targeting SRC in the treatment of breast cancer and other solid malignancies | Q37773087 |
| | Breast and cervical cancer in 187 countries between 1980 and 2010: a systematic analysis | Q37933638 |
| | Adjuvant endocrine therapy for breast cancer. | Q38032576 |
| | Suppression of breast cancer by chemical modulation of vulnerable zinc fingers in estrogen receptor | Q38346347 |
| | KX-01, a novel Src kinase inhibitor directed toward the peptide substrate site, synergizes with tamoxifen in estrogen receptor α positive breast cancer | Q39555328 |
| | Thiochroman derivative CH4986399, a new nonsteroidal estrogen receptor down-regulator, is effective in breast cancer models. | Q39714656 |
| | Definition of functionally important mechanistic differences among selective estrogen receptor down-regulators | Q40073529 |
| | Disruption of estrogen receptor DNA-binding domain and related intramolecular communication restores tamoxifen sensitivity in resistant breast cancer | Q40198718 |
| | Antitumor agents. 254. Synthesis and biological evaluation of novel neo-tanshinlactone analogues as potent anti-breast cancer agents | Q40238030 |
| | Antitumor Agents. 239. Isolation, structure elucidation, total synthesis, and anti-breast cancer activity of neo-tanshinlactone from Salvia miltiorrhiza | Q40499289 |
| | Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance | Q40536641 |
| | The effect of the new SERM arzoxifene on growth and gene expression in MCF-7 breast cancer cells | Q40554614 |
| | Oestrogen receptor-mediated modulation of the EGFR/MAPK pathway in tamoxifen-resistant MCF-7 cells. | Q40628338 |
| | Third-generation SERMs may face uphill battle | Q42829830 |
| | Breast cancer incidence in the randomized PEARL trial of lasofoxifene in postmenopausal osteoporotic women. | Q42836293 |
| | Progression and treatment of HER2-positive breast cancer | Q43189081 |
| | Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study. | Q43286764 |
| | Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study | Q43503861 |
| | A new antiestrogen, 2-(4-hydroxy-phenyl)-3-methyl-1-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-1H-indol-5-ol hydrochloride (ERA-923), inhibits the growth of tamoxifen-sensitive and -resistant tumors and is devoid of uterotropic effects in mice and rats | Q43763028 |
| | A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity | Q44004732 |
| | Development of cross-resistance to tamoxifen in raloxifene-treated breast carcinoma cells | Q44095179 |
| | Progesterone Receptor Status Significantly Improves Outcome Prediction Over Estrogen Receptor Status Alone for Adjuvant Endocrine Therapy in Two Large Breast Cancer Databases | Q44438551 |
| | A cancer research (UK) randomized phase II study of idoxifene in patients with locally advanced/metastatic breast cancer resistant to tamoxifen. | Q44727588 |
| | Characterization of new estrogen receptor destabilizing compounds: effects on estrogen-sensitive and tamoxifen-resistant breast cancer | Q44753981 |
| | Activity and safety of the antiestrogen EM-800, the orally active precursor of acolbifene, in tamoxifen-resistant breast cancer | Q44780580 |
| | Effects of raloxifene after tamoxifen on breast and endometrial tumor growth in athymic mice | Q45712907 |
| | The CYP2D6*4 polymorphism affects breast cancer survival in tamoxifen users | Q46135563 |
| | Evaluation of the safety and tolerability of oral TAS-108 in postmenopausal patients with metastatic breast cancer | Q46158830 |
| | Effects of fulvestrant 750mg in premenopausal women with oestrogen-receptor-positive primary breast cancer | Q46848091 |
| | Tamoxifen and estradiol interact with the flavin mononucleotide site of complex I leading to mitochondrial failure. | Q46892776 |
| | Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group. | Q53525799 |
| | A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer. | Q53626719 |
| | Inhibition of HER2/neu (erbB-2) and mitogen-activated protein kinases enhances tamoxifen action against HER2-overexpressing, tamoxifen-resistant breast cancer cells. | Q54031538 |
| | Antiproliferative effects of idoxifene in a placebo-controlled trial in primary human breast cancer. | Q54046476 |
| | Randomized phase II study of three doses of oral TAS-108 in postmenopausal patients with metastatic breast cancer. | Q64882370 |
| | Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate | Q74195354 |
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | tamoxifen | Q412178 |
| P304 | page(s) | 1023-35 | |
| P577 | publication date | 2013-06-01 | |
| P1433 | published in | Future Medicinal Chemistry | Q19280078 |
| P1476 | title | Development of new estrogen receptor-targeting therapeutic agents for tamoxifen-resistant breast cancer | |
| P478 | volume | 5 | |